On September 14, INNOVENT BIO rose 3.21% in regular trading, trading at 96.8 HKD/share, with turnover of approximately HKD 682 million.

On the news front, the World Lung Cancer Congress (WCLC), running from September 12 to 15, is serving as a major catalyst for the innovative drug sector. Multiple landmark clinical datasets from Chinese biotech companies are being presented at the conference, with AKESO's ivosdenib monotherapy overall survival data and B7H3 ADC results drawing particular attention. The sector-wide rally is evident, with AKESO up 5.92%, INNOCARE up 15.21%, 3SBIO up 4.99%, and SKB BIO up 3.22% within the Biotechnology sector.

Brokerages noted that the concentrated disclosure of lung cancer clinical progress at WCLC further validates the global competitiveness of Chinese innovative drugs. The pharmaceutical sector is currently trading at approximately 27x PE, below its historical average, with post-pullback allocation value becoming increasingly prominent. Multiple institutions maintain a bullish stance, citing Q3 revenue recognition from new orders and improving fundamentals. For INNOVENT BIO specifically, several major brokerages recently reiterated Buy ratings with target prices ranging from HKD 118 to HKD 146, supported by the company's strong H1 results showing 57% product revenue growth and a clear path toward its 2030 revenue target of RMB 35-40 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)